384 related articles for article (PubMed ID: 19601707)
1. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia.
Karagianis J; Williams R; Davis L; Procyshyn R; Monga N; Hanley J; Chandrasena R; Thakur A; Dickson R
Curr Med Res Opin; 2009 Sep; 25(9):2121-32. PubMed ID: 19601707
[TBL] [Abstract][Full Text] [Related]
2. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
3. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
4. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
[TBL] [Abstract][Full Text] [Related]
5. [Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].
Carpiniello B; Mellino G; Pintore S; Puddu L; Pinna F
Clin Ter; 2011; 162(4):331-41. PubMed ID: 21912821
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics.
Faries D; Ascher-Svanum H; Zhu B; Correll C; Kane J
BMC Psychiatry; 2005 May; 5():26. PubMed ID: 15921508
[TBL] [Abstract][Full Text] [Related]
8. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.
Byerly MJ; Nakonezny PA; Bettcher BM; Carmody T; Fisher R; Rush AJ
Schizophr Res; 2006 Sep; 86(1-3):244-50. PubMed ID: 16730951
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone.
Suzuki T; Uchida H; Watanabe K; Nakajima S; Nomura K; Takeuchi H; Tanabe A; Yagi G; Kashima H
Hum Psychopharmacol; 2008 Aug; 23(6):455-63. PubMed ID: 18537222
[TBL] [Abstract][Full Text] [Related]
10. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Rummel-Kluge C; Komossa K; Schwarz S; Hunger H; Schmid F; Lobos CA; Kissling W; Davis JM; Leucht S
Schizophr Res; 2010 Nov; 123(2-3):225-33. PubMed ID: 20692814
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.
Novick D; Ascher-Svanum H; Brugnoli R; Bertsch J; Hong J; Haro JM
J Nerv Ment Dis; 2012 Jul; 200(7):637-43. PubMed ID: 22759944
[TBL] [Abstract][Full Text] [Related]
12. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature.
Cohen D
Pharmacopsychiatry; 2004 Jan; 37(1):1-11. PubMed ID: 14750042
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).
Bitter I; Czobor P; Dossenbach M; Volavka J
Eur Psychiatry; 2005 Aug; 20(5-6):403-8. PubMed ID: 16084068
[TBL] [Abstract][Full Text] [Related]
14. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
[TBL] [Abstract][Full Text] [Related]
15. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
Sacchetti E; Valsecchi P; Parrinello G;
Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
Haro JM; Novick D; Suarez D; Roca M
J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.
Lambert M; Haro JM; Novick D; Edgell ET; Kennedy L; Ratcliffe M; Naber D
Acta Psychiatr Scand; 2005 Mar; 111(3):232-43. PubMed ID: 15701108
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
[TBL] [Abstract][Full Text] [Related]
20. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]